Keybank National Association OH Sells 1,354 Shares of Edwards Lifesciences Co. (NYSE:EW)

Keybank National Association OH cut its stake in Edwards Lifesciences Co. (NYSE:EW) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,873 shares of the medical research company’s stock after selling 1,354 shares during the period. Keybank National Association OH’s holdings in Edwards Lifesciences were worth $3,174,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $30,000. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth approximately $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Finally, Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 1.5 %

EW stock opened at $71.79 on Friday. The stock has a market cap of $42.34 billion, a P/E ratio of 10.30, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $72.36 and its two-hundred day simple moving average is $70.36. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,739 shares of company stock valued at $2,799,104 in the last three months. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on EW. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.